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Huntington’s disease (HD) is a fatal, inherited neurodegenerative disorder caused by an expanded CAG repeat 
in the gene encoding huntingtin (HTT). Therapeutic approaches to lower mutant HTT (mHTT) levels are 
expected to proceed to human trials, but noninvasive quantification of mHTT is not currently possible. The 
importance of the peripheral immune system in neurodegenerative disease is becoming increasingly recog-
nized. Peripheral immune cells have been implicated in HD pathogenesis, but HTT levels in these cells have 
not been quantified before. A recently described time-resolved Förster resonance energy transfer (TR-FRET) 
immunoassay was used to quantify mutant and total HTT protein levels in leukocytes from patients with HD. 
Mean mHTT levels in monocytes, T cells, and B cells differed significantly between patients with HD and con-
trols and between pre-manifest mutation carriers and those with clinical onset. Monocyte and T cell mHTT 
levels were significantly associated with disease burden scores and caudate atrophy rates in patients with HD. 
mHTT N-terminal fragments detected in HD PBMCs may explain the progressive increase in mHTT levels in 
these cells. These findings indicate that quantification of mHTT in peripheral immune cells by TR-FRET holds 
significant promise as a noninvasive disease biomarker.
Introduction
Huntington’s disease (HD) is caused by an autosomal dominant 
pathogenic mutation, resulting in an expanded stretch of 36 or 
more glutamine residues in the N terminus of the huntingtin 
(HTT) protein (1). Mutant HTT (mHTT) expression in the CNS 
is the primary pathogenic factor for the development of HD, with 
increasing expression levels associated with disease severity and 
toxicity in various models (2–4). However, patients with HD also 
exhibit multiple systemic changes (5). We have previously demon-
strated peripheral immune system dysfunction in HD, including 
increases in innate immune proteins in patient plasma, many of 
which track with disease progression (6). Inflammatory cytokines 
and chemokines are elevated in the plasma of patients with HD, 
the origin of which appears to be hyperreactive monocytes car-
rying the HD mutation (7, 8). Recent studies using peripherally 
administered kynurenine 3-monooxygenase inhibitors (9) and 
bone marrow transplantation (10) highlight further that the 
peripheral immune system is altered in HD. The hyperreactiv-
ity observed in monocytes is reflected by a similar pattern in HD 
microglia (7), and microglial activation is seen before symptom 
onset in HD mutation carriers (11). Peripheral immune dysfunc-
tion may be pathogenically important and could offer a window 
onto relevant CNS dysfunction.
Many putative therapeutic approaches for HD attempt to lower 
mHTT levels in the CNS or systemically. However, noninvasive 
means of quantifying mHTT in the CNS do not exist. Peripheral 
readouts may be of value in assessing the effects of systemically 
delivered HTT-lowering therapies, i.e., small molecules aimed 
at enhancing HTT clearance, and detecting peripheral effects of 
centrally delivered therapies. If mHTT levels track with disease 
progression, they may have value as markers of disease progres-
sion. Therefore, we aimed to use a recently described time-resolved 
Förster resonance energy transfer (TR-FRET) immunoassay (12) to 
quantify total HTT and mHTT levels in peripheral immune cells 
in patients with HD.
Results and Discussion
Whole blood was collected from 8 HD gene carriers without mani-
fest disease (pre-manifest patients), 10 early-stage and 8 moder-
ate-stage patients with HD, and 12 control subjects. Monocytes, 
T cells, and B cells were isolated using magnetic-activated cell sorting. 
Cheek swabs to harvest buccal epithelial cells were collected from 84 
subjects from the same experimental groups. Multiple swabs and/or 
blood samples were taken from some subjects. TR-FRET was used 
for the immunodetection of mutant and total HTT protein using 
HTT-specific antibodies (ref. 12 and Figure 1). Most patients with 
HD express mHTT with polyglutamine repeat lengths of 40 to 50 
residues (13), and the patient cohort used here was broadly within 
this range (Supplemental Table 1; supplemental material avail-
able online with this article; doi:10.1172/JCI64565DS1). TR-FRET 
analysis of an allelic series of purified HTT with increasing polyglu-
tamine repeat lengths showed 10- to 20-fold higher sensitivity for 
mHTT than that of the wild-type protein (Supplemental Figure 1 
and Supplemental Methods). Quality control experiments using 
repeated freeze-thaw cycles and different antibody pairs and fluo-
rophores indicated that the TR-FRET HTT assays were specific and 
reproducible (Supplemental Figure 2).
Total HTT levels did not differ significantly (P > 0.05) between 
patients with HD and controls (Figure 1A). mHTT levels in 
each cell type showed statistically significant (P < 0.001) dif-
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ferences between patients with HD and controls. Mean mHTT 
levels increased with successive disease stage in each leukocyte 
cell type, with differences (P < 0.01) between pre-manifest HD 
patients and patients with HD (manifest HD patients) and 
between pre-manifest and early-stage HD patients (0.021 < 
P < 0.051) but not between patients with early-stage and mod-
erate-stage HD (Figure 1B and Table 1). Such an increase was 
not observed in buccal cells (Supplemental Figure 3). Disease 
burden scores (14), which are based on an individual’s age 
and HTT CAG repeat length and correlate with clinically rel-
evant end points (15), were calculated for each patient with 
HD. After adjustment for age and gender, there was a strong 
(P < 0.001) positive association between disease burden and 
mHTT in monocytes and T cells (Figure 2A and Table 1). A sig-
nificant (P < 0.05) association was observed for B cells, but no 
evidence of an association was found in buccal epithelial cells 
(Supplemental Figure 4). Significant associations were also 
observed between CAG repeat length and mHTT (Supplemen-
tal Figure 5). No such associations were found between total 
HTT levels and disease burden score (data not shown).
Figure 1
Relationship between HTT levels in peripheral immune cells and disease stage. Total HTT and mHTT protein levels were quantified by TR-
FRET in monocytes, T cells, and B cells. Total HTT quantification relies on simultaneous binding of 2B7 and 2166 anti-HTT antibodies. mHTT 
is quantified using the 2B7 antibody and a polyglutamine-specific antibody, MW1. (A) Total HTT levels in leukocytes showed no significant 
differences between patients with HD and control subjects or between HD gene carriers at different disease stages. (B) mHTT protein was 
detected in samples from patients with HD and pre-manifest HD mutation carriers, as compared with that in controls. Differences in mean 
mHTT levels in leukocytes were observed between pre-manifest and manifest HD patients (P < 0.01) and between pre-manifest and early-
stage HD subjects (P = 0.051 and P < 0.05 for monocytes and T cells/B cells, respectively). Colored circles indicate multiple samples from 
a single subject. White circles indicate samples from individual subjects. Horizontal bars indicate the mean. Em, emission; Ex, excitation; N, 
N-terminal; C, C-terminal; Tb, terbium cryptate; polyQ, polyglutamine tract; pre-HD, pre-manifest HD sample; Early HD, early-stage HD sample; 
Moderate HD, moderate-stage HD sample.
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We also examined the relationship among leukocyte mHTT lev-
els and rates of caudate and whole brain atrophy and ventricular 
expansion in a subset of subjects with HD who had undergone 
3T MRI as part of the TRACK-HD study (15). Such atrophy rates 
provide a quantifiable measure of disease-associated changes in 
brain volume (15). mHTT levels in monocytes were significantly 
(P < 0.05) associated with rates of caudate and whole brain atro-
phy and ventricular expansion (Figure 2B, Supplemental Figure 
6, and Supplemental Table 2). The associations with caudate 
and whole brain atrophy were borderline significant in T cells 
(P = 0.086 and P = 0.049, respectively). To investigate whether 
the association between brain atrophy and mHTT levels merely 
reflects their mutual associations with disease burden, this factor 
was adjusted for in a secondary analysis. The association between 
mHTT and brain atrophy remained significant or close to signifi-
cant for caudate atrophy and ventricular expansion in monocytes 
(P = 0.007 and P = 0.093, respectively) and for caudate atrophy in 
T cells (P = 0.099) (Supplemental Table 2). These results must be 
interpreted cautiously due to the small sample size, but, to our 
knowledge, this is the first instance of a biochemical measure of 
a known pathogenic entity in peripheral cells that is significantly 
associated with measures of structural brain changes in a neuro-
degenerative disease.
There are several possible explanations for the progressive 
increase in mHTT levels in leukocytes with no concomitant differ-
ences in total HTT levels. An accumulation of mHTT over the life 
span of the cells is unlikely, because although some leukocytes are 
long-lived, monocytes typically persist for only 2 to 8 days in the 
bloodstream (16). Accumulation of extended CAG repeat expan-
sions in the HTT gene due to somatic DNA instability, another 
possible explanation, is not seen in peripheral immune cells (17). 
Selective increases in mHTT expression as the disease develops 
cannot be excluded, but this seems improbable as total HTT levels 
did not change. The most likely explanation is a progressive accu-
mulation of mHTT N-terminal fragments that are not detected in 
the TR-FRET total HTT signal.
mHTT fragments accumulate in HD rodent brain (18) and have 
been detected in HD patient brain postmortem (19, 20). Further-
more, HTT protein proteolysis has been demonstrated in lympho-
blast cell lines from patients with HD (21). To identify HTT frag-
ments in peripheral immune cells, a previously described unbiased 
immunoprecipitation and immunodetection strategy was used 
(18). This approach was chosen because although HTT fragments 
can be detected directly by Western blot, interpretation of such 
results is complicated by the cross-reactivity of some anti-HTT 
antibodies with other proteins. HTT was immunoprecipitated 
using anti-HTT antibodies (2B7, 2166, 4C9) from PBMCs from 
patients with early-stage HD and control subjects and immuno-
detected by Western blot (4C9, 2166) (Figure 3A). Several HTT 
fragments were immunoprecipitated, as detected by each of the 
anti-HTT antibodies.
Specifically detecting N-terminal mHTT fragments is difficult 
in samples in which the polyglutamine length is in the typical 
patient range of 40 to 50 CAG repeats. No antibodies are available 
that specifically detect either the wild-type or mHTT protein per 
se, and antibodies that distinguish between the two on the basis 
of polyglutamine-tract length only readily do so with many more 
CAG repeats. Therefore, HTT was detected in PBMCs isolated 
from patients with early-onset HD with 73 and 59 CAG repeats, 
compared with those from an aged-matched control subject (Fig-
ure 3B and Supplemental Figure 7). HTT was immunoprecipitat-
ed with the 2B7 and 2166 anti-HTT antibodies, as before, and also 
with the 3B5H10 antibody, which only recognizes an expanded 
polyglutamine tract and does not immunoprecipitate wild-type 
HTT. Similarly, HTT was immunodetected with the 2166 (Fig-
ure 3B) and 1H6 (Supplemental Figure 7) anti-HTT antibodies 
and also with the MW1 antibody (Figure 3B), which again only 
specifically recognizes an expanded polyglutamine tract. Using 
this approach, mHTT-specific fragments were readily identified 
in PBMCs from a patient with HD, compared with those from a 
control subject. Moreover, comparison of the mHTT fragments 
immunoprecipitated by the N-terminal 2B7 anti-HTT antibody 
with those from the more C-terminal 2166 antibody, indicated 
that some of the fragments were derived from the N terminus of 
the mHTT protein. This suggests that full-length mHTT is con-
tinuously cleaved to produce N-terminal fragments in patients’ 
peripheral immune cells.
Since noninvasive quantification of mHTT in CNS tissue or CSF 
in human subjects is not currently possible, the success of forth-
coming trials to lower mHTT levels will rely on indirect pharmaco-
dynamic outcome measures. Ex vivo testing of peripheral immune 
cells may be useful in identifying subjects in whom such therapies 
are most likely to succeed. Further research will determine whether 
the techniques described here can be used to monitor mHTT-lower-
ing therapies that may be expected to elicit systemic effects. Quan-
tifying the progressive, selective increase of mHTT protein levels in 
Table 1
P values for associations among cellular mHTT levels and disease stage and disease burden score, adjusted for age and gender
  Group comparison   Association with disease burden
 No. of observations/  P value   No. of observations/ P value
 subjects     subjects
  HD vs. Pre-HD vs. Early-stage HD  Moderate- vs.
  controlA manifest HDA vs.pre-HD early-stage HD
Monocytes 40/38 <0.001 0.007 0.051 0.404 26/25 <0.001
T cells 38/36 <0.001 0.001 0.021 0.217 24/23 <0.001
B cells 38/36 <0.001 <0.001 0.024 0.260 24/23 0.036
Buccal cells 98/84 <0.001 0.406 0.439 0.923 55/50 0.849
“Pre-HD vs. manifest” denotes comparisons between pre-manifest and manifest HD patients. “Early-stage HD vs. pre-HD” denotes comparisons between 
patients with early-stage HD and pre-manifest HD patients. “Moderate- vs. early-stage HD” denotes comparisons between patients with moderate-stage HD 
and those with early-stage HD. AEstimated using linear contrasts.
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peripheral immune cells may provide a valuable means, alongside 
other measures, of monitoring disease progression in HD. The 
meaning of longitudinal changes in mHTT levels in individual sub-
jects remains to be seen but is of interest. That mHTT levels in such 
cells appear to be associated both with disease progression and with 
brain atrophy rates indicates their potential relevance to pathogen-
ic and clinical events in the CNS. Future clinical trials in HD that 
aim to modulate mHTT levels directly or indirectly, and would be 
expected to act peripherally, may be enhanced by the application of 
such quantification.
Methods
Leukocyte isolation. Cells were isolated from whole blood as previously 
described (7). Briefly, 50 ml whole blood was collected in heparin (CP Phar-
maceuticals), and leukocytes were isolated by density gradient centrifuga-
tion. Leukocyte subsets were sorted via magnetic cell separation columns 
(Miltenyi Biotec) using anti-CD14, anti-CD3, and anti-CD19 microbeads 
for monocytes, T cells, and B cells, respectively. Pellets were snap-frozen 
and stored at –80°C until analysis.
Mutant and total HTT protein quantification by TR-FRET. TR-FRET was 
performed as previously described (12), with the following modifications. 
For every 1 × 106 cells, cells were lysed in 100 µl PBS, 1% Triton X-100, 
protease inhibitor cocktail (Roche). Cell lysates were added to 50 mM 
NaH2PO4, 400 mM NaF, 0.1% BSA, and 0.05% Tween and analyzed in 
white 384-well plates with 0.25 ng terbium cryptate (Tb) (Cisbio) conju-
gated 2B7 antibody and 20 ng D2 fluorophore (Cisbio) conjugated MW1 
antibody for mHTT, and 1 ng Tb conjugated 2B7 and 10 ng Alexa Fluor 
488 (A488) (Invitrogen) conjugated 2166 antibody for total HTT. Plates 
were rotated at 20 g for 30 seconds and incubated for 1 hour. Follow-
ing excitation of the Tb donor at 320 nm and a time delay of 100 µs, 
emission signals were measured at 620, 665, and 520 nm for Tb, D2, and 
A488, respectively. Ratios of 665:620 nm and 520:620 nm signals cor-
responded to mutant or total HTT levels. Total protein concentrations 
were determined by BCA assay (Pierce). Signals are reported as percent-
ages of signal intensities over lysis buffer background signals normalized 
to total protein concentration (difference in fluorescence intensity [ΔF]). 
All assays were carried out by an observer blinded to subject group (see 
Supplemental Table 3 for antibody details).
HTT fragment protein detection by immunoprecipitation and Western blot. 
HTT fragment protein detection was performed as described previously 
(18), with the following adaptations. PBMCs were lysed in 500 µl ice-cold 
lysis buffer (50 mM HEPES [pH 7.0], 150 mM NaCl, 10 mM EDTA, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1% BSA, 10 mM DTT, 
1 mM PMSF, 1x complete protease inhibitor cocktail [Roche]). Lysates 
Figure 2
Associations among mHTT levels in peripheral immune cells and disease burden score and caudate atrophy rate. (A) mHTT protein levels in 
leukocytes show a statistically significant positive association with HD disease burden score. Repeated measurements for a single subject are 
joined by a line. (B) mHTT levels in monocytes are significantly associated with caudate atrophy rates measured by serial volumetric MRI.
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were precleared prior to immunoprecipitation by incubation with 50 µl 
(1:1 slurry) prewashed G-Sepharose-agarose beads (Invitrogen) for 6 hours 
at 4°C. Immunoprecipitations were carried out overnight using 1 mg pre-
cleared supernatant, 20 µl protein G-Sepharose-agarose (1:1 slurry), and 
2 µg antibody in a 1 ml final volume. Beads were pelleted by centrifuga-
tion at 13,000 g for 30 seconds, washed 4 times with lysis buffer, resus-
pended in 8 µl 2× Laemmli buffer, and denaturated at 75°C for 5 minutes. 
Immunoprecipitates were separated by 8% SDS-PAGE and blotted onto 
nitrocellulose membranes for immunodetection (see Supplemental Table 
3 for antibody details).
Brain atrophy quantification. 3-Tesla volumetric MRI sequences were 
obtained using the TRACK-HD study London cohort. Details of the 
imaging protocols and rigorous quality control procedures are provided 
elsewhere (15). Follow-up scans were positionally matched to the base-
line images, and change over 36 months was calculated using the robust 
boundary shift integral technique (22). All boundary shift integral changes 
were annualized before statistical analysis. All image analysis was carried 
out by an observer blinded to subject identity and group.
Statistics. Linear regression models were used to compare HTT pro-
tein levels between groups, with adjustment for age and sex. Linear 
Figure 3
mHTT protein fragments are present in HD PBMCs. (A) HTT in PBMCs from 2 subjects with HD and an age-matched control was immunopre-
cipitated with 2166, 2B7, or 4C9 anti-HTT antibodies, as compared with that precipitated by an IgG control. Immunoprecipitates were blotted with 
4C9 and 2166 anti-HTT antibodies. Several HTT-specific bands were found in HD patient and control subject PBMC samples. (B) HTT protein in 
PBMCs from 2 patients with early-onset HD (HTT CAG repeat lengths of 76 and 59) and an age-matched control was immunoprecipitated with 
2B7, 3B5H10, or 2166 anti-HTT antibodies. Immunoprecipitates were blotted with either the polyglutamine-specific MW1 antibody or the 2166 
anti-HTT antibody. Several mHTT-specific bands were found in the lysates from the PBMCs from the patients with early-onset HD (colored boxes), 
including N-terminal HTT fragments (yellow boxes) immunoprecipitated with the 2B7 and 3B5H10 antibodies but not with the more C-terminal 
epitope-binding 2166. ID, immunodetection; IgG heavy chain, antibody heavy chain.
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contrasts were used to compare participants with HD and control par-
ticipants and pre-manifest and manifest subjects with HD. To allow 
for repeated measures for some subjects and potential heteroskedastic-
ity, Huber-White robust standard errors are reported (23, 24). Linear 
regression models with robust standard errors were used to investigate 
associations between HTT levels and disease burden after adjustment 
for age and gender. To relate brain atrophy to mHTT levels, ordinary 
least-squares regression models were fitted, using mean mHTT levels 
in the case of multiple measures, again adjusting for age and gender. 
Throughout, statistically significant P values were taken to be those 
less than 0.05 (2 sided). Disease burden score was calculated as follows: 
[CAG repeat length – 35.5] × age. All analysis was performed using 
STATA v12.
Study approval. Experiments were performed in accordance with the Dec-
laration of Helsinki and approved by UCL/UCL Hospitals Joint Research 
Ethics Committee. All subjects gave informed written consent. Subject 
inclusion criteria and clinical assessments were used, and CAG repeat 
lengths were measured in RNA, as previously described (7).
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